Relationships of circulating Sex Hormone-Binding Globulin with Metabolic Traits in Humans

Andreas Peter, MD¹, Konstantinos Kantartzis, MD¹, Jürgen Machann, PhD², Fritz Schick, MD, PhD², Harald Staiger, PhD¹, Fausto Machicao, PhD¹, Erwin Schleicher, PhD¹, Andreas Fritsche, MD¹, Hans-Ulrich Häring, MD¹, Norbert Stefan, MD¹

Running title: SHBG and Metabolic Traits

¹Department of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Medicine, Nephrology and Clinical Chemistry, University of Tübingen, member of the German Center for Diabetes Research (DZD), Tübingen, Germany
²Section on Experimental Radiology, University of Tübingen, Tübingen, Germany

Address for correspondence
Norbert Stefan, MD
email: norbert.stefan@med.uni-tuebingen.de

Submitted 4 February 2010 and accepted 3 September 2010.

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
**Objective:** Recent data suggested that sex hormone-binding globulin (SHBG) levels decrease when fat accumulates in the liver and that circulating SHBG may be causally involved in the pathogenesis of type 2 diabetes in humans. In the present study we investigated mechanisms by which high SHBG may prevent development to diabetes.

**Research Design and Methods:** Before and during a 9 month lifestyle intervention total body- and visceral fat were precisely measured by magnetic resonance (MR) tomography and liver fat by $^1$H-MR spectroscopy in 225 subjects. Insulin sensitivity was estimated from a 75-g oral glucose tolerance test (IS$_{OGTT}$) and measured by a euglycemic, hyperinsulinemic clamp (IS$_{clamp}$, n=172). Insulin secretion was measured during the OGTT and an ivGTT (n=172).

**Results:** SHBG levels correlated positively with insulin sensitivity (IS$_{OGTT}$: p=0.037; IS$_{clamp}$: p=0.057), independently of age, gender and total body fat. In a multivariate model these relationships were also significant after additional adjustment for levels of the adipokine adiponectin and the hepatokine fetuin-A (IS$_{OGTT}$: p=0.0096; IS$_{clamp}$: p=0.029). Adjustment of circulating SHBG for liver fat abolished the relationships of SHBG with insulin sensitivity. In contrast, circulating SHBG correlated negatively with fasting glycemia, before (r=-0.17, p=0.009) and after adjustment for liver fat (r=-0.14, p=0.04). No correlation of circulating SHBG with adjusted insulin secretion was observed (OGTT: p=0.16; ivGTT: p=0.35). The SNP rs1799941 in SHBG was associated with circulating SHBG (p≤0.025), but not with metabolic characteristics (all p>0.18).

**Conclusions:** Possible mechanisms by which high circulating SHBG prevents the development of type 2 diabetes involve regulation of fasting glycemia, but not alteration of insulin secretory function.

Recently, two studies applying the Mendelian randomization approach, an elegant tool to study causal relationships between plasma parameters and traits in humans (1), suggested that circulating sex hormone-binding globulin (SHBG) may be involved in the pathogenesis of type 2 diabetes in men and in women (2;3). Because circulating SHBG regulates biological action and signaling of sex hormones (4), these data strengthen the notion that sex hormones play an important role in the pathogenesis of the disease. So far, however, results from several studies revealed that this field of research is very complex. While high testosterone levels were found to be associated with insulin resistance, glucose intolerance and increased risk of type 2 diabetes in women, in men high testosterone levels appear to protect from insulin resistance and diabetes. In contrast, in both sexes, although not consistent among all studies, high estradiol levels were associated with elevated insulin resistance and increased risk of type 2 diabetes (5;6).

For relationships of circulating SHBG with insulin sensitivity and risk of type 2 diabetes, the data were more consistent among sexes. Low plasma levels of SHBG were found to be similarly strongly associated with insulin resistance and increased risk of type 2 diabetes, in men and in women in most (7-11), but not in all studies (12-15).

The question now is; besides genetic variability in SHBG, which parameters...
involved in the natural history of type 2 diabetes regulate plasma levels of SHBG? Studies indicated that high insulin levels decrease the release of SHBG from hepatocytes (16;17), which represent the major source of SHBG biosynthesis (18). However, Selva et al. provided convincing evidence that expression of SHBG in hepatocytes could be suppressed by glucose or fructose, strong inducers of hepatic lipogenesis (19), but not by insulin (20). This is in agreement with human studies showing that low circulating SHBG was not associated with elevated insulin levels (21), but with obesity and dyslipidemia, conditions that are strongly associated with fatty liver in humans (22-29). Based on the data from Selva et al. (20) we hypothesized that specifically fatty liver may be associated with low circulating SHBG in humans, and we could recently support this in a small study (30).

Because of the unexpected finding of no significant relationships between genetic variants in SHBG and metabolic traits in the study by Perry et al. (3), in the present study we investigated mechanisms behind the association between low SHBG levels and increased risk of type 2 diabetes in our precisely phenotyped subjects. Therefore, we additionally genotyped them for a variant which was found to be strongly associated with plasma SHBG levels and the risk of type 2 diabetes (3).

RESEARCH DESIGN AND METHODS

Subjects. Caucasians from the southern part of Germany participated in the ongoing Tübingen Lifestyle Intervention Program (TULIP) (31-33). Individuals were included into the study when they fulfilled at least one of the following criteria: a family history of type 2 diabetes, a BMI > 27 kg/m², previous diagnosis of impaired glucose tolerance or gestational diabetes. In a small pilot study we previously investigated relationships of circulating SHBG with total body fat, visceral fat and liver fat in a total of 114 subjects (30). One hundred and seven subjects from that study, had these measurements and blood samples, both, at baseline and after 9 months of lifestyle intervention and were also included in the present study. We subsequently included another set of 118 subjects, who met the aforementioned requirements, resulting in a total of 225 subjects in the present study.

Subjects were considered healthy according to a physical examination and routine laboratory tests. As assessed by means of a standard questionnaire, the participants had no history of liver disease such as hepatitis, and did not consume more than 2 alcoholic drinks per day. Informed written consent was obtained from all participants and the local medical ethics committee had approved the protocol.

Lifestyle intervention. After the baseline measurements, individuals underwent dietary counselling and had up to ten sessions with a dietician. Counselling was aimed to reduce body weight, intake of calories and particularly intake of calories from fat, and to increase intake of fibres. No specific recommendations regarding protein intake were given. Individuals were asked to perform at least 3 hours of moderate sports per week. Aerobic endurance exercise (e.g. walking, swimming) with an only moderate increase in the heart rate was encouraged. Participants were seen by the staff on a regular basis to ensure that these recommendations were accomplished. Furthermore, all subjects completed a standardized and validated questionnaire to estimate physical activity and a habitual physical activity (HPA) score was calculated.

Body fat distribution and liver fat. Waist circumference was measured at the midpoint between the lateral iliac crest and lowest rib. Furthermore, we measured total- and visceral fat with an axial T1-weighed fast spin echo
technique with a 1.5 T whole-body imager (Magnetom Sonata, Siemens Healthcare) (34). Volunteers were in prone position and images were recorded from fingers to toes with a slice thickness of 10 mm and a gap between slices of 10 mm. Segmentation of images was performed by semiautomatic thresholding based on a Matlab routine (Mathworks, Inc.). Visceral fat was quantified in 16 to 21 slices (depending on the size of the volunteer) between femoral heads and diaphragm, not differentiating between intra- and retroperitoneal fat, by manual delineation of the visceral compartment. Fat volume from images was calculated by multiplying the in-plane pixel dimensions with the slice thickness and the number of pixels classified as fat. Volumes between contiguous slices are calculated by simply doubling the volume of the adjacent slice. Liver fat was measured by localized $^1$HMR spectroscopy as previously described (34).

**Maximal aerobic capacity (VO$_{2\text{max}}$).** Individuals underwent a continuous, incremental exercise test to volitional exhaustion using a cycle ergometer. The cycle ergometer test was performed on an electromagnetically braked cycle ergometer (Ergometrics 800 S; Ergoline, Bitz, Germany). Oxygen consumption was measured using a spiroergometer (MedGraphics System Breese Ex 3.02 A; MedGraphics). VO$_{2\text{max}}$ is expressed as VO$_2$ (ml/min) per kg body weight (ml·min$^{-1}$·kg$^{-1}$).

**Oral glucose tolerance test.** All individuals underwent a 75 g oral glucose tolerance test (OGTT). We obtained venous plasma samples at 0, 30, 60, 90 and 120 minutes for determination of plasma glucose and insulin. Glucose tolerance was determined according to the 1997 World Health Organization diagnostic criteria (35).

**Euglycemic, hyperinsulinemic clamp.** Insulin sensitivity was determined with a primed insulin infusion at a rate of 40 mU·m$^2$·min$^{-1}$ for 2 hours as previously described (34).

**Analytical procedures.** Blood glucose was determined using a bedside glucose analyzer (glucose-oxidase method; YSI, Yellow Springs Instruments, Yellow Springs, OH). Plasma insulin and C-peptide were determined by microparticle enzyme immunoassays (ADVIA Centaur, Siemens Healthcare Diagnostics, Eschborn, Germany). Fasting plasma levels of adiponectin were determined with enzyme-linked immunosorbent assays (ELISA, Linco Research, Inc., St Charles, MO). Fasting plasma levels of fetuin-A were measured by an immunoturbidimetric method (BioVendor Laboratory Medicine, Modreci, Czech Republic). Serum SHBG levels were measured using the fully automated solid-phase, chemiluminescent immunoassay IMMULITE 2500 (Siemens Healthcare Diagnostics, Eschborn, Germany).

**Calculations.** The insulin sensitivity index measured during the clamp (in µmol·kg$^{-1}$·min$^{-1}$·pM$^{-1}$) was calculated as the mean infusion rate of glucose (in µmol·kg$^{-1}$·min$^{-1}$) necessary to maintain euglycemia during the last 40 minutes of the euglycemic hyperinsulinemic clamp divided by the steady state plasma insulin concentration. The latter was the mean insulin concentration at minute 100, 110 and 120 of the clamp. Insulin sensitivity from the OGTT was estimated as proposed by Matsuda and DeFronzo (36). The insulinogenic index was assessed from the OGTT as follows: (insulin at 30 min - insulin at 0 min)/(glucose at 30 min – glucose at 0 min). Insulin secretion during the IVGTT was assessed as the sum of C-peptide levels and insulin levels, respectively, during the first 10 min after glucose administration.

**Genotyping.** For genotyping, DNA was isolated from whole blood using a commercial DNA isolation kit (NucleoSpin, Macherey & Nagel, Düren, Germany). The SNP rs1799941
in SHBG (37;38) which was found to be associated with circulating SHBG and type 2 diabetes (3), was genotyped using TaqMan assay (Applied Biosystems, Foster City, CA, USA). The TaqMan genotyping reaction was amplified on a GeneAmp PCR system 7000 (50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min), and fluorescence was detected on an ABI Prism sequence detector (Applied Biosystems, Foster City, CA, USA). The TaqMan assay was validated by direct sequencing of the SNP in 50 subjects, and both methods gave identical results. The genotyping success rate for the SNP rs1799941 was 99.9% and re-screening of 3.3% of the subjects with the TaqMan assay gave 100% identical results.

 Statistical analyses. Data that were not normally distributed (e.g. liver fat, circulating SHBG, insulin sensitivity, body fat distribution; Shapiro-Wilk W test) were logarithmically transformed. Differences between baseline and follow-up were tested using the matched pairs t test. Univariate associations between parameters were tested using Pearson correlation analyses. To adjust the effects of covariates and identify independent relationships, multivariate linear regression analyses were used. To test the effect of the genotype on the metabolically relevant parameters, the parameter to be considered was set as the dependent variable. The genotype was included in both analyses as an independent nominal variable. The statistical software package JMP 5.1 (SAS Institute Inc, Cary, NC, USA) was used.

 RESULTS
 Characteristics of all 225 subjects. Anthropometrics and metabolic characteristics of the 225 subjects at baseline (table 1) covered a wide range that was particularly large for total body fat, visceral fat, liver fat, insulin sensitivity and circulating SHBG. A total of 66 subjects had fatty liver (liver fat > 5.56%) (39).

 Circulating SHBG was lower in males than females (means±SE; 24.8±1.1 vs 56.2±4.3 %, p<0.0001) and did not correlate significantly with age (r=0.01, p=0.17) or VO2max (r=0.10, p=0.16).

 During the lifestyle intervention measures of total- and visceral adiposity and liver fat decreased and physical activity and VO2max increased (table 1). A decrease was also found for fasting and 2h glycemia and insulinemia. While insulin sensitivity increased, measures of insulin secretion remained unchanged. Hs-CRP levels decreased and adiponectinemia increased. Circulating SHBG also increased. Regarding dietary intake, at baseline circulating SHBG correlated negatively with total energy intake (r=-0.28, p<0.0001), but not with percentage of carbohydrate-, fat- or protein intake. During the intervention a trend for a larger increase in circulating SHBG with larger decrease in carbohydrate intake was observed (r=-0.10, p=0.13).

 Relationships of circulating SHBG with total body fat, visceral fat and liver fat at baseline and during the lifestyle intervention in 118 subjects. First we tested whether we can replicate our previous findings of a strong and independent relationship of circulating SHBG with liver fat in the 118 subjects that were not included in our previous analysis about relationships of circulating SHBG with total body-, visceral- and liver fat (30). In the 118 subjects circulating SHBG adjusted for gender and age correlated negatively with total body-, visceral- and liver fat (table 2). In multivariate linear regression analyses including age, gender, liver-, total body- and visceral fat, liver fat (F-value: 11, p=0.0016) was the strongest determinant of circulating SHBG, followed by gender (F-value: 6, p=0.017), while total body- (F-value: <1, p=0.62) and
visceral fat (F-value: <1, p=0.61) were not independent determinants. Based on the strong correlations between liver fat and circulating SHBG, we then tested whether an increase in circulating SHBG was specifically found in subjects in whom a large decrease in liver fat was observed. Indeed, there was a strong correlation between change in liver fat with change in circulating SHBG (r=-0.37, p<0.0001). Negative correlations, albeit weaker in magnitude, were also found between changes in circulating SHBG with total body- (r=-0.28, p=0.0018) and visceral fat (r=-0.23, p=0.011). In a multivariate analysis change in liver fat correlated with change in circulating SHBG, independently of gender, age and changes in total body- and visceral fat (r=-0.29, p=0.0023). In this model changes in total body and visceral fat did not correlate with changes in circulating SHBG anymore (both p≥0.24).

**Relationship between circulating SHBG and metabolic characteristics in 225 subjects.** We next investigated whether circulating SHBG correlated with metabolic traits in 225 subjects. SHBG levels were negatively associated with fasting glycemia (r=-0.17, p=0.009), but not with fasting insulinemia (r=-0.07, p=0.27), after adjustment for gender, age and total body fat. Furthermore, no correlations with adjusted 2h glycemia (r=-0.04, p=0.55) or insulinemia (r=-0.10, p=0.12) during the OGTT were found. Prior to testing whether additional adjustment for liver fat modulated the relationships of fasting glycemia with SHBG levels and to avoid overadjustment, we first searched for a parsimonious model. In a stepwise regression model including the parameters sex, total body fat, age, SHBG levels and additionally liver fat, the latter three were determinants of fasting glycemia. In a multivariate model including these three parameters, the relationship between circulating SHBG with fasting glycemia was significant (r=-0.14, p=0.04).

SHBG levels did not correlate with measurements of insulin secretion from the OGTT (r=0.09, p=0.16) or the iVTT (r=0.07, p=0.35), adjusted for gender, age, total body fat and insulin sensitivity estimated from the OGTT. In contrast, positive correlations between circulating SHBG with insulin sensitivity estimated from the OGTT (r=0.14, p=0.037) and measured by the clamp (r=0.15, p=0.057), adjusted for gender, age and total body fat, were found. Prior to the inclusion of liver fat in these models, again stepwise linear regression analyses were performed. In these models circulating SHBG was not a determinant of insulin sensitivity (OGTT: p=0.88; clamp: p=0.63).

We then investigated whether circulating SHBG impacts on insulin sensitivity independently of adiponectin and fetuin-A levels, parameters that were found to determine insulin sensitivity and incident diabetes (40-44). In multivariate regression models we first found that both, adiponectin and fetuin-A were independent determinants of insulin sensitivity. Interestingly, circulating SHBG also turned out to be an independent determinant of insulin sensitivity, both estimated from the OGTT and measured by the clamp (table 3).

**Relationship between the rs1799941 SNP in SHBG with metabolic characteristics.** In our population, the SNP rs1799941 in *SHBG* was in Hardy-Weinberg equilibrium (χ²-test; p≥0.97) and the allele frequency of the minor A allele was 0.29. In agreement with Perry et al. (3) we found that carriers of the minor A allele had higher circulating SHBG, independently of gender, age and total body fat (p=0.025). This relationship became stronger after additional adjustment for the important determinant of circulating SHBG, liver fat (p=0.007). Also in agreement with Perry et al. (3), we found no significant
relationships of the SNP with fasting glycemia or insulinemia, insulin sensitivity, estimated from the clamp and the OGTT or measurements of insulin secretion (all \( p > 0.18 \)).

**DISCUSSION**

Two recently published studies using the Mendelian randomization approach, provided strong evidence that circulating SHBG is directly involved in the pathogenesis of type 2 diabetes, both in men and in women (2;3). This may now help to more deeply address the complex, but doubtlessly important role of sex hormones in the natural history of the disease. However, prior to this, it is critical to understand which mechanisms involved in the pathogenesis of type 2 diabetes, regulate circulating SHBG. Certainly genetic variability in SHBG is a candidate. Although the studies addressing this issue consistently found the SNPs in SHBG to be associated with SHBG levels in humans, the variants explained merely about 2\% of the variance in circulating levels of the protein (2;37). Therefore, other mechanisms appear to be more important in the regulation of circulating SHBG.

Selva et al. convincingly showed that glucose- and fructose-induced hepatic lipogenesis, via decrease in cellular hepatocyte nuclear factor-4α, inhibits hepatic SHBG expression *in vitro* and in mice (20). Based on the fact that hepatic lipogenesis is strongly associated with fatty liver in humans (19), we could recently show that elevated liver fat content strongly correlated with circulating SHBG in humans (30). In the present study we could replicate these findings in an independent group of subjects. In univariate cross-sectional analyses both, total body- and visceral adiposity correlated negatively with circulating SHBG. However, when liver fat was included in these analyses, the relationships became non-significant. Using data from our longitudinal lifestyle intervention study, we were then also able to investigate which parameters were associated with change in circulating SHBG. In agreement with the cross-sectional data, we found that subjects having the largest decrease in total body fat, visceral fat or liver fat, also had the largest increase in SHBG levels during the intervention. Furthermore, in multivariate analyses, also in the longitudinal data, changes in total body- or visceral fat were no more associated with change in circulating SHBG, but change in liver fat still correlated negatively with change in SHBG levels. These findings suggest that any correlation observed between measures of total body- and visceral adiposity with SHBG levels, is most probably driven by liver fat.

What is the novel impact of these findings on future research or interventions? From a pathophysiological aspect these data support that interventions specifically inhibiting or reducing hepatic lipogenesis, may represent the most promising tools to increase SHBG levels in humans. So far recommendation of diets with a low glycemic index or a low carbohydrate content, may be the most efficient and safe intervention. While it is still not solved, whether such diets are superior to other nutritional approaches to reduce body weight (45;46), there is clear evidence that they are very efficient in improving dyslipidemia and parameters of glucose metabolism, even when the effect on body weight was small (45;47). Now it would be very important to study whether a low glycemic index diet is particularly effective in decreasing liver fat and increasing circulating SHBG in humans.

Besides carefully investigating parameters increasing SHBG levels, our aim of the present study was to investigate by which mechanisms SHBG levels impact on type 2 diabetes. First, we were very surprised learning from the study by Perry et al (3), that SNPs which were clearly associated with
both, circulating SHBG and the prevalence of type 2 diabetes, were not associated with any measures of type 2 diabetes related traits in population based studies. It may well be that different assays used to measure insulin and glucose between the studies may have made the data difficult to interpret. Furthermore, it is possible that the effect of the SNPs on circulating SHBG is small. This is supported by the little variance in SHBG levels that can be explained by the SNP rs1799941, which showed the strongest association with SHBG levels (3;37). Consequently, also in our study, this SNP was not associated with insulinemia, glycemia, or measures of insulin sensitivity or insulin secretion.

However, we found a significant negative correlation of circulating SHBG with fasting glycemia. Interestingly, no correlation with fasting insulinemia was observed. These findings argue against the hypothesis that hyperinsulinemia is responsible for the decline in SHBG levels in humans and support that glucose may be involved in the regulation of SHBG production. Alternatively, it is also possible that SHBG may impact on hepatic gluconeogenesis, the most important determinant of fasting glycemia (48) in humans. This hypothesis is supported by the fact that the correlation between circulating SHBG and fasting glycemia remained statistically significant, even after adjustment for fasting insulinemia (p=0.002) or liver fat. Regarding whole-body insulin sensitivity, we provide novel data that circulating SHBG was a determinant of this parameter, which was estimated from the OGTT and measured by the clamp, independently of established humoral factors, the adipokine adiponectin (40;43;49) or the hepatokine fetuin-A (41;50), that are associated with liver fat and regulate whole-body insulin sensitivity. This finding suggests that SHBG may be involved in the regulation of whole-body insulin sensitivity via mechanisms, which not necessarily involve adiponectin or fetuin-A signaling. Interestingly, circulating SHBG did not correlate with measurements of whole-body insulin sensitivity after further adjustment for liver fat. This is in contrast to the results regarding fasting glycemia. A conservative interpretation of these data would result in the conclusion that circulating SHBG may impact on hepatic glucose production, but not on insulin-mediated glucose disposal. In the future studies in humans with tracer methods may help to precisely address this question. Furthermore, no correlation of circulating SHBG with insulin secretion was found. For these analyses we used two measures of insulin secretion, the insulinogenic index obtained from the OGTT, representing an estimate of glucose- and incretin-induced insulin secretion and the ivGTT, a powerful tool to measure glucose-induced insulin secretion. These data argue against a major role of circulating SHBG in the pathogenesis of beta cell dysfunction in humans.

Altogether, when summarizing the data in the literature in the field of SHBG research and our present data, the following hypothetical picture emerges regarding causes and metabolic consequences of circulating SHBG in humans (figure): first, also in our replication cohort, SHBG levels strongly correlated with liver fat in cross-sectional and in longitudinal analyses, supporting that conditions regulating fat accumulation in the liver affect circulating SHBG. Second, because the SNP rs1799941 of \textit{SHBG} associated with SHBG levels independently of liver fat, genetic variability in \textit{SHBG} directly appears to regulate the circulating levels of the protein. Third, the relationships of SHBG levels with whole-body insulin sensitivity are most probably explained by liver fat. Fourth, a significant relationship of SHBG levels with fasting glycemia, which was independent of liver fat, was found. Because fasting glycemia is most strongly affected by hepatic...
glycogenolysis and/or gluconeogenesis (48), our findings suggest that SHBG may have direct effects on hepatic glucose production. Increased hepatic glucose output in concert with a beta-cell defect might explain the association of circulating SHBG and SHBG genetic variants with type 2 diabetes.

In conclusion, using cross-sectional and longitudinal data in an independent group of subjects, we can now support our previous findings that high liver fat most strongly associates with low circulating SHBG. Possible mechanisms by which high circulating SHBG prevents the development of type 2 diabetes involve regulation of fasting glycemia, but not alteration of insulin secretory function.

**Author Contributions.** A.P. and N.S. researched data and wrote the manuscript. J. M., F. S., H. S., F.M., A.F. researched data and edited the manuscript. E.S. and HU.H. edited the manuscript and contributed to the discussion.

**ACKNOWLEDGEMENTS**
The study was supported by grants from the Deutsche Forschungsgemeinschaft (KFO 114 and a Heisenberg-Grant to NS, STE 1096/1-1) and in part by a grant from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.). We thank all the participants for their cooperation and Mareike Walenta, Roman Werner, Alke Guirguis, and the phenotyping team, all from the Department of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Medicine, Nephrology and Clinical Chemistry, University of Tübingen, Germany, for their help to collect the data.

**FIGURE LEGEND**
Hypothetical picture regarding cause and metabolic consequences of circulating SHBG in humans

Conditions regulating fat accumulation in the liver and the SNP rs1799941 of SHBG are candidates affecting circulating SHBG. In contrast, visceral adiposity does not appear to directly affect circulating SHBG. The relationships of SHBG levels with whole-body insulin sensitivity are most probably explained by liver fat. The significant relationship of SHBG levels with fasting glycemia, which was independent of liver fat, supports that SHBG may have direct effects on hepatic glucose production. Increased hepatic glucose output in concert with a beta-cell defect might explain the association of circulating SHBG and SHBG genetic variants with type 2 diabetes.

**REFERENCES**
1. Schunkert,H, Samani,NJ: Elevated C-reactive protein in atherosclerosis--chicken or egg? *N. Engl. J. Med.* 359:1953-1955, 2008
2. Ding,EL, Song,Y, Manson,JE, Hunter,DJ, Lee,CC, Rifai,N, Buring,JE, Gaziano,JM, Liu,S: Sex hormone-binding globulin and risk of type 2 diabetes in women and men. *N. Engl. J. Med.* 361:1152-1163, 2009
3. Perry, JR, Weedon,MN, Langenberg,C, Jackson,AU, Lyssenko,V, Sparso,T, Thorleifsson,G, Grallert,H, Ferrucci,L, Maggio,M, Paolisso,G, Walker,M, Palmer,CN, Payne,F, Young,E, Herder,C, Narisu,N, Morken,MA, Bonnycastle,LL, Owen,KR, Shields,B, Knight,B, Bennett,A, Groves,CJ, Ruokonen,A, Jarvelin,MR, Pearson,E, Pascoe,L, Ferrannini,E, Bornstein,SR,
Stringham, HM, Scott, LJ, Kuusisto, J, Nilsson, P, Neptin, M, Gjesing, AP, Pisinger, C, Lauritzen, T, Sandbaek, A, Sampson, M, Zeggini, ME, Lindgren, CM, Steinthorsdottir, V, Thorsteinsdottir, U, Hansen, T, Schwarz, P, Illig, T, Laakso, M, Stefansson, K, Morris, AD, Groop, L, Pedersen, O, Boehnke, M, Barroso, I, Wareham, NJ, Hattersley, AT, McCarthy, MI, Frayling, TM: Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. *Hum. Mol. Genet.* 19:535-544, 2010

4. Kahn, SM, Hryb, DJ, Nakhla, AM, Romas, NA, Rosner, W: Sex hormone-binding globulin is synthesized in target cells. *J. Endocrinol.* 175:113-120, 2002

5. Ding, EL, Song, Y, Malik, VS, Liu, S: Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA* 295:1288-1299, 2006

6. Haffner, SM: Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. *Int. J. Obes. Relat. Metab. Disord.* 24 Suppl 2:S56-S58, 2000

7. Birkeland, KI, Hanssen, KF, Torjesen, PA, Vaaler, S: Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. *J. Clin. Endocrinol. Metab* 76:275-278, 1993

8. Muller, M, Grobbee, DE, den, T, I, Lamberts, SW, van der Schouw, YT: Endogenous sex hormones and metabolic syndrome in aging men. *J. Clin. Endocrinol. Metab* 90:2618-2623, 2005

9. Pitteloud, N, Mootha, VK, Dwyer, AA, Hardin, M, Lee, H, Eriksson, KF, Tripathy, D, Yialamas, M, Groop, L, Elahi, D, Hayes, FJ: Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. *Diabetes Care* 28:1636-1642, 2005

10. Sowers, M, Derby, C, Janneausch, ML, Torrens, JI, Pasternak, R: Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN. *J. Clin. Endocrinol. Metab* 88:4904-4910, 2003

11. Tsai, EC, Matsumoto, AM, Fujimoto, WY, Boyko, EJ: Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. *Diabetes Care* 27:861-868, 2004

12. Abate, N, Haffner, SM, Garg, A, Peshock, RM, Grundy, SM: Sex steroid hormones, upper body obesity, and insulin resistance. *J. Clin. Endocrinol. Metab* 87:4522-4527, 2002

13. Ando, S, Rubens, R, Rottiers, R: Androgen plasma levels in male diabetics. *J. Endocrinol. Invest* 7:21-24, 1984

14. Jang, Y, Lee, JH, Cho, EY, Chung, NS, Topham, D, Balderston, B: Differences in body fat distribution and antioxidant status in Korean men with cardiovascular disease with or without diabetes. *Am. J. Clin. Nutr.* 73:68-74, 2001

15. Ozata, M, Oktenli, C, Bingol, N, Ozdemir, IC: The effects of metformin and diet on plasma testosterone and leptin levels in obese men. *Obes. Res.* 9:662-667, 2001

16. Crave, JC, Lejeune, H, Brebant, C, Baret, C, Pugeat, M: Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells. *J. Clin. Endocrinol. Metab* 80:1283-1289, 1995

17. Plymate, SR, Jones, RE, Matej, LA, Friedl, KE: Regulation of sex hormone binding globulin (SHBG) production in Hep G2 cells by insulin. *Steroids* 52:339-340, 1988

18. Khan, MS, Knowles, BB, Aden, DP, Rosner, W: Secretion of testosterone-estradiol-binding globulin by a human hepatoma-derived cell line. *J. Clin. Endocrinol. Metab* 53:448-449, 1981

19. Browning, JD, Horton, JD: Molecular mediators of hepatic steatosis and liver injury. *J. Clin. Invest* 114:147-152, 2004
20. Selva, DM, Hogeveen, KN, Innis, SM, Hammond, GL: Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. *J.Clin.Invest* 117:3979-3987, 2007

21. Sutton-Tyrrell, K, Wildman, RP, Matthews, KA, Chae, C, Lasley, BL, Brockwell, S, Pasternak, RC, Lloyd-Jones, D, Sowers, MF, Torrens, JI: Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). *Circulation* 111:1242-1249, 2005

22. Kotronen, A, Yki-Jarvinen, H: Fatty liver: a novel component of the metabolic syndrome. *Arterioscler.Thromb.Vasc.Biol.* 28:27-38, 2008

23. Roden, M: Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. *Nat.Clin.Pract.Endocrinol.Metab* 2:335-348, 2006

24. Stefan, N, Kantartzis, K, Haring, HU: Causes and metabolic consequences of Fatty liver. *Endocr.Rev.* 29:939-960, 2008

25. Utzschneider, KM, Kahn, SE: Review: The role of insulin resistance in nonalcoholic fatty liver disease. *J.Clin.Endocrinol.Metab* 91:4753-4761, 2006

26. Wagenknecht, LE, Scherzinger, AL, Stamm, ER, Hanley, AJ, Norris, JM, Chen, YD, Bryer-Ash, M, Haffner, SM, Rotter, JI: Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. *Obesity.(Silver.Sprin)* 17:1240-1246, 2009

27. Targher, G, Marra, F, Marchesini, G: Increased risk of cardiovascular disease in nonalcoholic fatty liver disease: causal effect or epiphenomenon? *Diabetologia* 51:1947-1953, 2008

28. Deivanayagam, S, Mohammed, BS, Vitola, BE, Naguib, GH, Keshen, TH, Kirk, EP, Klein, S: Nonalcoholic fatty liver disease is associated with hepatic and skeletal muscle insulin resistance in overweight adolescents. *Am.J.Clin.Nutr.* 88:257-262, 2008

29. Petersen, KF, Dufour, S, Befroy, D, Lehrke, M, Hendler, RE, Shulman, GI: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. *Diabetes* 54:603-608, 2005

30. Stefan, N, Schick, F, Haring, HU: Sex hormone-binding globulin and risk of type 2 diabetes. *N.Engl.J.Med.* 361:2675-2676, 2009

31. Kantartzis, K, Thamer, C, Peter, A, Machann, J, Schick, F, Schraml, C, Konigsrainer, A, Konigsrainer, I, Krober, S, Niess, A, Fritsche, A, Haring, HU, Stefan, N: High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. *Gut* 58:1281-1288, 2009

32. Kantartzis, K, Peter, A, Machicao, F, Machann, J, Wagner, S, Konigsrainer, I, Konigsrainer, A, Schick, F, Fritsche, A, Haring, HU, Stefan, N: Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. *Diabetes* 58:2616-2623, 2009

33. Stefan, N, Kantartzis, K, Machann, J, Schick, F, Thamer, C, Rittig, K, Balletshofer, B, Machicao, F, Fritsche, A, Haring, HU: Identification and characterization of metabolically benign obesity in humans. *Arch.Intern.Med.* 168:1609-1616, 2008

34. Stefan, N, Machicao, F, Staiger, H, Machann, J, Schick, F, Tschritter, O, Spieth, C, Weigert, C, Fritsche, A, Stumvoll, M, Haring, HU: Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. *Diabetologia* 48:2282-2291, 2005

35. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 20:1183-1197, 1997
36. Matsuda, M, DeFronzo, RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. *Diabetes Care* 22:1462-1470, 1999

37. Ahn, J, Schumacher, FR, Berndt, SI, Pfeiffer, R, Albanes, D, Andriole, GL, Ardanaz, E, Boeing, H, Bueno-de-Mesquita, B, Chanock, SJ, Clavel-Chapelon, F, Diver, WR, Feigelson, HS, Gaziano, JM, Giovannucci, E, Haiman, CA, Henderson, BE, Hoover, RN, Kolonel, LN, Kraft, P, Ma, J, Le Marchand, L, Overvad, K, Palli, D, Stattin, P, Stampfer, M, Stram, DO, Thomas, G, Thun, MJ, Travis, RC, Trichopoulou, D, Virtamo, J, Weinstein, SJ, Yeager, M, Kaaks, R, Hunter, DJ, Hayes, RB: Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). *Hum. Mol. Genet.* 18:3749-3757, 2009

38. Melzer, D, Perry, JR, Hernandez, D, Corsi, AM, Stevens, K, Rafferty, I, Lauretani, F, Murray, A, Gibbs, JR, Paolisso, G, Rafiq, S, Simon-Sanchez, J, Lango, H, Scholz, S, Weedon, MN, Arepalli, S, Rice, N, Washecka, N, Hurst, A, Britton, A, Henley, W, van de, LJ, Li, R, Newman, AB, Tranah, G, Harris, T, Panicker, V, Dayan, C, Bennett, A, McCarthy, MI, Ruokonen, A, Jarvelin, MR, Guralnik, J, Bandinelli, S, Frayling, TM, Singleton, A, Ferrucci, L: A genome-wide association study identifies protein quantitative trait loci (pQTLs). *PLoS. Genet.* 4:e1000072, 2008

39. Szczepaniak, LS, Nurenberg, P, Leonard, D, Browning, JD, Reingold, JS, Grundy, S, Hobbs, HH, Dobbins, RL: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. *Am. J. Physiol Endocrinol. Metab* 288:E462-E468, 2005

40. Trujillo, ME, Scherer, PE: Adipose tissue-derived factors: impact on health and disease. *Endocr. Rev.* 27:762-778, 2006

41. Stefan, N, Hennige, AM, Staiger, H, Machann, J, Schick, F, Krober, SM, Machicao, F, Fritsche, A, Haring, HU: Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. *Diabetes Care* 29:853-857, 2006

42. Stefan, N, Fritsche, A, Weikert, C, Boeing, H, Joost, HG, Haring, HU, Schulze, MB: Plasma fetuin-A levels and the risk of type 2 diabetes. *Diabetes* 57:2762-2767, 2008

43. Kadowaki, T, Yamauchi, T: Adiponectin and adiponectin receptors. *Endocr. Rev.* 26:439-451, 2005

44. Ix, JH, Wassel, CL, Kanaya, AM, Vittinghoff, E, Johnson, KC, Koster, A, Cauley, JA, Harris, TB, Cummings, SR, Shlipak, MG: Fetuin-A and incident diabetes mellitus in older persons. *JAMA* 300:182-188, 2008

45. Thomas, DE, Elliott, EJ, Baur, L: Low glycaemic index or low glycaemic load diets for overweight and obesity. *Cochrane Database Syst. Rev.* CD005105, 2007

46. Nordmann, AJ, Nordmann, A, Briel, M, Keller, U, Yancy, WS, Jr., Brehm, BJ, Bucher, HC: Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Arch. Intern. Med.* 166:285-293, 2006

47. Buyken, AE, Mitchell, P, Ceriello, A, Brand-Miller, J: Optimal dietary approaches for prevention of type 2 diabetes: a life-course perspective. *Diabetologia* 2010 (epub ahead of print) DOI: 10.1007/s00125-009-1629-8

48. Meyer, C, Pimenta, W, Woeerle, HJ, Van Haeften, T, Szeke, E, Mitrakou, A, Gerich, J: Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. *Diabetes Care* 29:1909-1914, 2006

49. Stefan, N, Vozarova, B, Funahashi, T, Matsuzawa, Y, Weyer, C, Lindsay, RS, Youngren, JF, Havel, PJ, Pratley, RE, Bogardus, C, Tataranni, PA: Plasma adiponectin concentration is associated
with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. *Diabetes* 51:1884-1888, 2002

50. Auberger, P, Falquerho, L, Contreres, JO, Pages, G, Le Cam, G, Rossi, B, Le Cam, A: Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. *Cell* 58:631-640, 1989

### Table 1 Subject characteristics at baseline and at follow-up in all 225 subjects

| Parameter                        | Baseline       | Follow-up      | p-value   |
|----------------------------------|----------------|----------------|-----------|
| Gender (males/females)           | 90/135         |                |           |
| Age (years)                      | 47 (19-69)     | 48 (20-70)     | <0.0001   |
| Body weight (kg)                 | 86.2 (52.5-144.7) | 84.0 (52.0-142.8) | <0.0001   |
| Waist circumference (cm)         | 96.5 (63.0-135.0) | 92.0 (66.5-131.5) | <0.0001   |
| Body mass index (kg · m⁻²)       | 29.0 (19.4-43.5) | 27.9 (18.9-42.9) | <0.0001   |
| Total body fat MRT (kg)          | 24.9 (4.0-61.0) | 21.9 (0.2-57.5) | <0.0001   |
| Visceral fat MRT (kg)            | 2.59 (0.25-9.73) | 2.04 (0.15-10.72) | <0.0001   |
| Liver fat MRS (%)                | 3.10 (0.16-30.88) | 2.09 (0.00-23.21) | <0.0001   |
| HPA score                        | 8.13 (3.510-11.00) | 8.50 (5.32-11.38) | <0.0001   |
| VO₂max (ml·min⁻¹·kg⁻¹)           | 24.5 (9.5-54.1) | 25.0 (2.0-47.1) | 0.03      |
| Fasting glucose (mM)             | 5.17 (4.33-7.42) | 5.11 (4.11-7.31) | 0.0012    |
| 2h glucose (mM)                  | 6.67 (4.17-11.17) | 6.39 (3.50-13.39) | 0.004     |
| Fasting insulin (pM)             | 50 (19-373)     | 43 (14-175)    | <0.0001   |
| 2h insulin (pM)                  | 395 (47-2132)   | 310 (37-3112)  | <0.0001   |
| Insulin sensitivity OGTT (arb. units) | 11.7 (1.6-32.1) | 13.2 (2.4-39.2) | <0.0001   |
| Insulin secretion OGTT (pM/mg/dl) | 109 (25-2346)   | 110 (16-9197)  | 0.28      |
| Insulin secretion ivGTT (pM)     | 6937 (1731-16162) | 7152 (2527-26462) | 0.54      |
| Hs-CRP (mg/dl)                   | 0.12 (0.01-2.31) | 0.08 (0.01-1.78) | 0.001     |
| SHBG (nM)                        | 29.8 (7.2-283.0) | 33.6 (9.0-287.0) | <0.0001   |
| Adiponectin (µg/ml)              | 12.0 (3.0-53.0) | 14.0 (4.0-117.2) | <0.0001   |
| Fetuin-A (µg/ml)                 | 258 (126-478)   |                |           |

Data represent unadjusted medians (range). Differences between baseline and follow-up were tested using the matched pairs *t* test. MRT: magnetic resonance tomography; MRS: magnetic resonance spectroscopy; HPA: habitual physical activity; VO₂max: maximal aerobic capacity. *Available in 200 subjects at baseline and at follow-up. § At baseline available in 172 and at follow-up in 47 subjects.
Table 2 Correlations between circulating SHBG and fat compartments at baseline adjusted for gender and age in the subgroup of 118 subjects

|                      | Visceral fat | Liver fat | Circulating SHBG |
|----------------------|--------------|-----------|------------------|
|                      | r            | p         | r                | p             |
| Visceral fat         | 0.72         | <0.0001   | 0.35             | 0.0002        |
| Liver fat            | -0.22        | 0.016     | -0.28            | 0.0022        |
| Total body fat       | 0.54         | <0.0001   | -0.40            | <0.0001       |

Total body- and visceral fat were measured by magnetic resonance (MR) tomography and liver fat by $^1$HMR spectroscopy.

Table 3 Determinants of insulin sensitivity in multivariate linear regression models

| Covariates          | Insulin sensitivity$_{OGTT}$ Estimate ± SE | p     | Insulin sensitivity$_{Clamp}$ Estimate ± SE | p     |
|---------------------|--------------------------------------------|-------|---------------------------------------------|-------|
| **Model 1**         |                                            |       |                                             |       |
| Female sex          | 0.16 ± 0.04                                | <0.0001 | 0.17 ± 0.04                                | <0.0001 |
| Age                 | -0.004 ± 0.130                             | 0.98  | -0.06 ± 0.13                                | 0.66  |
| Total body fat      | -0.58 ± 0.09                               | <0.0001 | -0.60 ± 0.09                                | <0.0001 |
| **Model 2**         |                                            |       |                                             |       |
| Female sex          | 0.11 ± 0.04                                | 0.01  | 0.08 ± 0.04                                 | 0.06  |
| Age                 | -0.29 ± 0.14                               | 0.04  | -0.27 ± 0.14                                | 0.06  |
| Total body fat      | -0.47 ± 0.09                               | <0.0001 | -0.50 ± 0.09                                | <0.0001 |
| Adiponectin levels  | 0.25 ± 0.09                                | 0.007 | 0.38 ± 0.09                                 | <0.0001 |
| Fetuin-A levels     | -0.76 ± 0.20                               | 0.0002 | -0.47 ± 0.21                                | 0.027 |
| **Model 3**         |                                            |       |                                             |       |
| Female sex          | 0.06 ± 0.04                                | 0.19  | 0.03 ± 0.05                                 | 0.46  |
| Age                 | -0.30 ± 0.14                               | 0.03  | -0.26 ± 0.14                                | 0.07  |
| Total body fat      | -0.42 ± 0.09                               | <0.0001 | -0.47 ± 0.09                                | <0.0001 |
| Adiponectin levels  | 0.22 ± 0.09                                | 0.01  | 0.37 ± 0.09                                 | <0.0001 |
| Fetuin-A levels     | -0.83 ± 0.20                               | <0.0001 | -0.50 ± 0.21                                | 0.018 |
| SHBG levels         | 0.16 ± 0.06                                | 0.0096 | 0.14 ± 0.06                                 | 0.029 |
High caloric diet → Visceral adiposity → FAT → Circulating SHBG → ? Hepatic glucose production → Genetic variability in SHBG → + Impaired beta-cell function → Type 2 Diabetes